SEARCH

SEARCH BY CITATION

References

  • 1
    Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. HEPATOLOGY 2003; 38: 493502.
  • 2
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. HEPATOLOGY 2007; 45: 579587.
  • 3
    Di Marco V, Almasio PL, Ferraro D, Calvaruso V, Alaimo G, Peralta S, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47: 484491.
  • 4
    The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. HEPATOLOGY 1994; 20: 1520.
  • 5
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 6
    O'Brien MJ, Keating NM, Elderiny S, Cerda S, Keaveny AP, Afdhal NH, et al. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol 2000; 114: 712718.
  • 7
    Goodman ZD, Becker RL, Pockros PJ, Afdhal NH. Progression of fibrosis in chronic hepatitis C: evaluation by morphometric image analysis. HEPATOLOGY 2007; 45: 886894.
  • 8
    Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003; 38: 14491457.
  • 9
    McHutchison J, Goodman Z, Maklouf HR, Rodriguez–Torres M, Shiffman ML, Rockey DC, et al. Double-blind, randomized, placebo-controlled, multi-center phase II dose-ranging study to assess the antifibrotic activity of farglitazar in chronic hepatitis C infection. HEPATOLOGY 2008; 48( Suppl): 11391140.
  • 10
    Di Bisceglie AM, Schiffman ML, Everson GT, Lindsay KL, Everhardt JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low dose peginterferon. New Engl J Med 2008; 359: 24292441.
  • 11
    Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 472492.
  • 12
    Skinner HA. Development and validation of a lifetime alcohol consumption assessment procedure. Toronto, Canada: Addiction Research Foundation, 1982.
  • 13
    Shiffman ML, Morishima C, Lindsay KL, Hoefs JC, Dienstag JL, Szabo G, et al.; HALT-C Trial Group. Suppression of serum HCV RNA levels during maintenance peginterferon (PEGIFN) alfa-2a therapy and clinical outcomes in the HALT-C Trial. J Hepatol 2008; 48( Suppl 2): S62.
  • 14
    Sherman KE, Goodman ZD, Sullivan ST, Faris-Young S. Liver biopsy in cirrhotic patients. Am J Gastroenterol 2007; 102: 789793.
  • 15
    Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239244.